Genomics vs Proteomics vs Metabolomics: What Each One Measures
Genomics measures what your cells could do, proteomics measures what they are doing, and metabolomics measures what happened as a result. The genome is a fixed three-billion-letter reference that you can sequence once and query forever. The proteome is a tissue-specific and time-varying inventory of the machines built from that reference. The metabolome is the downstream chemistry: sugars, lipids, amino acids, organic acids, and microbial products whose concentrations shift within minutes of a meal or a run. The technologies sit at different points on a causal chain, and they differ in cost, stability, interpretability, and how much of the answer they can give you alone 1. They are not competing technologies.
What each layer measures and how fast it changes
The genome is the only layer you can call “done.” A single whole-genome sequencing run at 30x average coverage gives you a lifetime asset. Your germline variants do not change, so the analysis cost is entirely in reinterpretation as knowledge bases improve.
The transcriptome sits between the genome and the proteome and is worth naming separately, because it is the cheapest way to see regulation in action. RNA sequencing of whole blood tells you which genes are transcribed and at what level, plus splicing patterns and allele-specific expression. Transcript levels shift on a timescale of hours.
The proteome is where most drug targets and most clinically actionable biology live. Protein abundance correlates only loosely with mRNA abundance. Translation rate, protein half-life, and post-translational modification all intervene. Plasma protein levels move over days to weeks for most analytes and within hours for acute-phase reactants.
The metabolome is the fastest and least buffered layer. Glucose, lactate, ketones, and many amino acids respond to a single meal. This is precisely why metabolomics is not predictable from the genome sequence: metabolic network state depends on flux, enzyme kinetics, and environment in ways that genotype alone does not determine 2.
What you get back as files
The practical difference between these layers shows up the moment you look at the data on disk.
Genomics gives you FASTQ from the instrument, then an aligned CRAM or BAM against GRCh38 or T2T-CHM13, then a VCF or gVCF of variant calls. A 30x human genome is roughly 90 to 100 GB of gzipped FASTQ and 25 to 30 GB as CRAM. Expect on the order of four to five million variants against the reference, the overwhelming majority of which are common and benign. The standard pipeline is bwa-mem2 mem -t 16 -K 100000000 -Y, then samtools sort, then either GATK HaplotypeCaller or DeepVariant. We prefer DeepVariant for single-sample germline calling because its indel precision is better out of the box and it needs less tuning. Structural variants need a separate caller such as Manta or Delly, and short reads will miss a meaningful fraction of them regardless.
RNA sequencing gives you FASTQ again, then either a genome-aligned BAM from STAR or a transcript-level quantification from salmon quant -l A --validateMappings --gcBias. The output quant.sf file has one row per transcript with TPM and estimated counts. For a single person you cannot run a differential expression test against a control group, so the useful unit is a longitudinal series of your own samples analyzed with DESeq2 or limma-voom on the time axis.
Proteomics splits into two families with very different outputs. Affinity assays such as Olink and SomaScan give you a clean matrix: roughly 3,000 proteins as normalized protein expression values for Olink Explore, or about 7,000 aptamer targets as an .adat file for SomaScan. Mass spectrometry proteomics gives you raw vendor files, converted to open mzML with msconvert, then searched with FragPipe or DIA-NN against a UniProt human FASTA. The output is a protein group table with intensities. Plasma is the hard matrix, because albumin and immunoglobulins dominate and the dynamic range of the plasma proteome spans about ten orders of magnitude.
Metabolomics comes as mzML or vendor raw, processed with XCMS, MZmine 3, or MS-DIAL into a feature table of mass-to-charge ratio, retention time, and intensity. Untargeted runs typically produce thousands of features. Most of them will never be identified to a named compound. Targeted panels give you far fewer analytes with actual concentrations and far better reliability.
Where each layer fails
Genomics fails at prediction. Knowing you carry a variant tells you about risk distributions, not about your current state, and most variants in any individual genome are of uncertain significance. It also fails on regions that short reads cannot resolve: segmental duplications, repeat expansions, and the highly polymorphic HLA and pharmacogene loci such as CYP2D6.
Proteomics fails at coverage and at cross-platform agreement. Affinity platforms measure only the proteins on the panel, and binder specificity is a real concern. Mass spectrometry of undepleted plasma reaches a few hundred to a couple of thousand proteins, which leaves most of the low-abundance signaling proteome invisible.
Metabolomics fails at annotation and at reproducibility. A feature at a given mass and retention time is a hypothesis about a molecule until you match it against an authentic standard. Batch effects between runs are severe, and pre-analytical variables like time-to-freeze change the answer.
How we would combine them
Use the genome as the interpretive prior and the downstream layers as the evidence. The clearest demonstration of this pattern comes from rare disease work, where RNA sequencing and proteomics resolve genomic variants of uncertain significance by showing whether transcript or protein is lost 3. A splice-region variant that looks ambiguous in a VCF becomes convincing when RNA-seq shows exon skipping and proteomics shows a missing protein.
The same logic applies to common biology. The genome says which pathway is worth watching. The proteome and metabolome say whether that pathway is currently perturbed in you. Cancer research has converged on the same integrated framing, because no single layer captures both the driver lesion and the phenotype it produces 4. Biomarker programs in other fields have followed the same route. They combine genomic, proteomic, and metabolomic measurements rather than betting on one 5.
Practically, we would sequence the genome once, then repeat the fast layers on a schedule. Quarterly blood draws for proteomics and metabolomics, paired with continuous glucose data, give you a personal time series where each analyte is its own control. Personal baselines beat population reference intervals, because the within-person variation for most proteins and metabolites is much smaller than the between-person spread.
Two constraints matter. First, pre-analytical handling dominates data quality for the fast layers, so fix your collection protocol before you optimize your pipeline. Second, interpretation of any clinically meaningful finding belongs with a physician or a genetic counselor. These are measurement tools, and the translation from measurement to medical decision is not a data problem 6.
Questions people also ask
Which layer should I measure first? The genome, because it is a one-time cost that never expires and it tells you which downstream signals deserve attention. If you can only afford recurring measurement, standard blood biomarkers plus continuous glucose give you more actionable signal per dollar than untargeted metabolomics.
Can I predict my proteome or metabolome from my genome? No. Genotype constrains the system but does not determine its state, and metabolic behavior in particular is poorly predicted by sequence alone 2. Genetic variants do explain a portion of the variance in specific protein levels, which is useful for anchoring causal claims.
Is transcriptomics part of genomics? They are usually treated as separate layers. Genomics reads DNA, transcriptomics reads the RNA produced from it, and the two answer different questions 1.
Why are metabolomics results so hard to reproduce? Because concentrations move on the timescale of hours, most untargeted features are unannotated, and instrument batch effects are large. Targeted panels with internal standards are far more reliable when you need actual numbers.
Do I need all three? For most questions about your own health, a genome plus a repeated panel of proteins, metabolites, and standard labs answers more than any single deep layer. Integration is where the value sits 4.
Footnotes
-
Richard P Horgan, Louise C Kenny. ‘Omic’ technologies: genomics, transcriptomics, proteomics and metabolomics. The Obstetrician & Gynaecologist, 2011. https://doi.org/10.1576/toag.13.3.189.27672 ↩ ↩2
-
Wolfram Weckwerth. Unpredictability of metabolism—the key role of metabolomics science in combination with next-generation genome sequencing. Analytical and Bioanalytical Chemistry, 2011. https://doi.org/10.1007/s00216-011-4948-9 ↩ ↩2
-
Sarah L. Stenton, Laura S. Kremer, Robert Kopajtich, et al. The diagnosis of inborn errors of metabolism by an integrative “multi‐omics” approach: A perspective encompassing genomics, transcriptomics, and proteomics. Journal of Inherited Metabolic Disease, 2019. https://doi.org/10.1002/jimd.12130 ↩
-
Juan Casado-Vela, Arancha Cebrián, María Teresa Gómez del Pulgar, et al. Approaches for the study of cancer: towards the integration of genomics, proteomics and metabolomics. Clinical and Translational Oncology, 2011. https://doi.org/10.1007/s12094-011-0707-9 ↩ ↩2
-
Charitharth Vivek Lal, Vineet Bhandari, Namasivayam Ambalavanan. Genomics, microbiomics, proteomics, and metabolomics in bronchopulmonary dysplasia. Seminars in Perinatology, 2018. https://doi.org/10.1053/j.semperi.2018.09.004 ↩
-
Craig Russell, Ayesha Rahman, Afzal R Mohammed. Application of genomics, Proteomics and Metabolomics in Drug discovery, Development and Clinic. Therapeutic Delivery, 2013. https://doi.org/10.4155/tde.13.4 ↩
Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.